August 25, 2017 / 6:49 AM / in 4 months

BRIEF-Kyowa Hakko Kirin says U.S. FDA grants breakthrough therapy designation for Mogamulizumab

Aug 25 (Reuters) - Kyowa Hakko Kirin Co Ltd -

* US Food and Drug Administration grants breakthrough therapy designation for Mogamulizumab for the treatment of Mycosis Fungoides and Sézary Syndrome

* Initiated discussions with other regulatory authorities concerning plans for marketing authorization applications for Mogamulizumab in CTCL Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below